Universität zu Köln

Schildhaus, Hans-Ulrich, Schroeder, Lars, Merkelbach-Bruse, Sabine, Binot, Elke, Buettner, Reinhard, Kuhn, Walther and Rudlowski, Christian (2013). Therapeutic strategies in male breast cancer: Clinical implications of chromosome 17 gene alterations and molecular subtypes. Breast, 22 (6). S. 1066 - 1072. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080

Full text not available from this repository.

Abstract

Male breast cancer (MBC) is a rare disease. To date, therapy is mainly based on studies and clinical experiences with breast cancer in women. Only little is known about molecular typing of MBC, particularly with regard to potential biological predictors for adjuvant therapy. In female breast cancer tumors with chromosome 17 centromere (CEP17) duplication, HER2 and/or Topoisomerase II alpha (Topo II-alpha) gene alterations have been suggested to be associated with poor prognosis and increased sensitivity to anthracycline-containing regimens. In a well characterized cohort of 96 primary invasive MBC, we studied CEP17, HER2 and Topo II-alpha alterations by fluorescence in-situ hybridization (FISH), and expression of hormone receptors (HR), HER2 and Ki67 by immunohistochemistry to define molecular subtypes. Tumor characteristics and follow-up data were available and correlated with molecular findings. HER2 amplification and Topo II-alpha amplification/deletion were exceptionally rare in MBC (6.3% and 3.1%, respectively). CEP17 polysomy were found in 9.4% of tumors. HER2, Topo II-alpha and CEP17 gene alterations were not correlated to patients outcome. 96.9% of our cases were HR positive. Triple negative tumors were found in only 3.1% of the cases. In nodal negative tumors luminal A subtypes were significantly associated with better overall survival. Our results provide evidence for a predominant male breast cancer phenotype, characterized by HR expression and a lack of HER2/Topo II-alpha alterations and CEP17 duplicates. Therefore, the impact of anthracycline sensitivity linked to HER2/Topo II-alpha alterations as found in female breast cancer has low clinical significance for this specific male breast cancer phenotype. (C) 2013 Elsevier Ltd. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schildhaus, Hans-Ulrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Schroeder, Lars UNSPECIFIED UNSPECIFIED UNSPECIFIED Merkelbach-Bruse, Sabine UNSPECIFIED UNSPECIFIED UNSPECIFIED Binot, Elke UNSPECIFIED UNSPECIFIED UNSPECIFIED Buettner, Reinhard UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuhn, Walther UNSPECIFIED UNSPECIFIED UNSPECIFIED Rudlowski, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-471143
DOI:	10.1016/j.breast.2013.08.008
Journal or Publication Title:	Breast
Volume:	22
Number:	6
Page Range:	S. 1066 - 1072
Date:	2013
Publisher:	CHURCHILL LIVINGSTONE
Place of Publication:	EDINBURGH
ISSN:	1532-3080
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language TOPOISOMERASE-II-ALPHA; ADJUVANT CHEMOTHERAPY; HER2 AMPLIFICATION; PREDICTIVE-VALUE; EXPRESSION; CARCINOMA; DOXORUBICIN; FEMALE; CYCLOPHOSPHAMIDE; ANTHRACYCLINES Multiple languages Oncology; Obstetrics & Gynecology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/47114